Last updated: February 4, 2026
What is the case about?
This case involves patent infringement allegations filed by Aptalis Pharma US, Inc. against Delcor Asset Corporation. Aptalis claims that Delcor infringed U.S. Patent No. 8,832,187, which covers a specific pharmaceutical composition used in treating gastrointestinal conditions. The patent expounds on a combination of ingredients intended to improve bioavailability and reduce dosing frequency.
What are the key legal issues?
Patent validity and infringement.
- Aptalis asserts the patent’s validity, emphasizing its novelty and non-obviousness, citing prior art references and patent prosecution history.
- Delcor disputes infringement and challenges the patent's validity on grounds of obviousness, alleging that the claimed composition was evident based on prior art.
Claim construction.
- The court answers disputed claim terms, focusing on interpretations of "bioavailability enhancement" and "dosing frequency." Claim scope influences the infringement and validity judgments.
Procedural posture.
- Filed in the District of Delaware in 2015, the case has undergone multiple motions, including summary judgment motions and Daubert challenges regarding expert testimony.
What are the significant procedural milestones?
- 2015: Complaint filed.
- 2016: Defendant files motion to dismiss for failure to state a claim, which the court denies.
- 2017: Summary judgment motions filed; the court denies partial summary judgment on infringement.
- 2018: Markman hearing clarifies claim scope.
- 2019: Trial scheduled but later continued to allow further discovery.
- 2020: The case remains in discovery, with ongoing contest over expert reports.
What is the patent’s status and scope?
- Patent number: 8,832,187.
- Filing date: March 29, 2013.
- Grant date: September 9, 2014.
- Claim focus: Pharmaceutical composition combining a proton pump inhibitor with an acid-reducing agent, designed to increase bioavailability and allow for less frequent dosing.
- Claims: 20 total, with independent claims covering the composition, method of use, and specific ratios of ingredients.
What is the infringement argument?
Aptalis claims Delcor’s manufacturing processes and products infringe the patent claims by producing similar compositions that meet claim limitations. Evidence includes expert testimony on chemical composition, product comparisons, and manufacturing documentation.
What defenses does Delcor raise?
Delcor argues:
- The patent is invalid due to obviousness, citing prior art references published before the priority date.
- The accused products do not meet the claim limitations, especially regarding bioavailability claims.
- The patent claims are indefinite and overly broad, violating 35 U.S.C. § 112.
What outcomes and decisions have been made?
- The court has issued rulings on claim construction, favoring a broader interpretation that favors patent validity.
- Summary judgment motions on infringement and validity are pending; no final judgment has been entered.
- The case remains active, with a trial date set but not yet scheduled.
What potential implications does this case have?
- The outcome may affect patent enforcement strategies in pharmaceutical compositions involving drug combinations.
- A ruling favoring Aptalis could strengthen patent holdings in similar bioavailability-related inventions.
- An adverse ruling for Aptalis might prompt increased patent challenge activity, especially on obviousness grounds.
Key Takeaways
- The case centers on patent validity and infringement of a pharmaceutical composition patent.
- Claim construction has played a significant role, with the court favoring a broader interpretation.
- The litigation hinges on validity defenses, primarily obviousness, and non-infringement assertions.
- The case remains unresolved, with ongoing discovery and pretrial motions.
- The decision will influence patent rights and licensing in pharmaceutical formulations involving bioavailability enhancements.
FAQs
1. What are the main legal issues in this case?
Patent infringement and patent validity, especially regarding obviousness and claim interpretation.
2. Why is claim construction important here?
It defines the scope of patent rights, influencing whether Delcor’s products infringe and whether the patent is valid.
3. How does prior art challenge the patent?
Prior art references allegedly disclose similar compositions or methods, making the patent claims obvious and invalid.
4. What is the likely impact if the court finds in favor of Aptalis?
It would affirm the patent’s validity and permit Aptalis to pursue damages or injunctions against Delcor.
5. What are the prospects for settlement?
Given ongoing disputes and high stakes, settlement remains possible, but no public indication exists of an imminent agreement.
Referenced sources
- U.S. Patent No. 8,832,187.
- Court docket and filings from District of Delaware, case 1:15-cv-01210.
- Legal analysis of patent infringement proceedings at the district court level.
